John Litchfield
Pfizer (United States)(US)
Publications by Year
Research Areas
Drug Transport and Resistance Mechanisms, Pancreatic function and diabetes, Pharmacogenetics and Drug Metabolism, Diabetes Treatment and Management, Pharmacological Effects and Toxicity Studies
Most-Cited Works
- → Identification of Glyoxal and Arabinose as Intermediates in the Autoxidative Modification of Proteins by Glucose(1995)590 cited
- → New biomarkers of Maillard reaction damage to proteins(1996)164 cited
- → Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions(2012)129 cited
- → Targeting Intestinal Transporters for Optimizing Oral Drug Absorption(2010)128 cited
- → Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach(2017)128 cited
- → pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1(2011)118 cited
- → Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus(2011)115 cited
- → Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1(2011)102 cited
- → Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle(2009)80 cited
- → AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats(2003)77 cited